Exelixis
EXEL
#1347
Rank
NZ$28.82 B
Marketcap
NZ$118.14
Share price
-1.82%
Change (1 day)
56.77%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2026 (TTM): NZ$1.86 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.49 Billion. In 2025 the company made an earning of NZ$1.72 Billion, an increase over its 2024 earnings that were of NZ$1.24 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.86 B8.46%
2025 NZ$1.72 B38.08%
2024 NZ$1.24 B164.69%
2023 NZ$0.47 B9.89%
2022 NZ$0.42 B-20.33%
2021 NZ$0.53 B124.82%
2020 NZ$0.23 B-67.14%
2019 NZ$0.72 B-11.94%
2018 NZ$0.82 B185.09%
2017 NZ$0.28 B-325.82%
2016 -NZ$0.13 Billion-58.12%
2015 -NZ$0.31 Billion-37.61%
2014 -NZ$0.5 Billion9.75%
2013 -NZ$0.45 Billion65.96%
2012 -NZ$0.27 Billion-291.63%
2011 NZ$0.14 B-195.59%
2010 -NZ$0.15 Billion-42.17%
2009 -NZ$0.26 Billion-18.98%
2008 -NZ$0.32 Billion-6.99%
2007 -NZ$0.34 Billion46.3%
2006 -NZ$0.24 Billion33.25%
2005 -NZ$0.18 Billion-30.92%
2004 -NZ$0.26 Billion44.29%
2003 -NZ$0.18 Billion12.86%
2002 -NZ$0.16 Billion22.79%
2001 -NZ$0.13 Billion60.14%
2000 -NZ$78.36 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$34.22 B 1,656.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$12.73 B 553.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$20.20 B 936.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$14.23 B 630.69%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$12.28 B 530.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$20.71 B 963.20%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$13.07 B 571.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-NZ$15.45 Million-100.79%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-NZ$53.09 Million-102.72%๐Ÿ‡บ๐Ÿ‡ธ USA